ABSTRACT
The increase in the frequency of COVID-19 is closely related to the fact that the number of patients in Russia who have had COVID-19 is currently increasing every day. At the same time, many of them continue to experience symptoms after an acute infection regardless of its severity, which is of concern to the entire medical community. In this context, it is important to remem-ber that COVID-19 is characterized not only by lesions of the respiratory system, but also by damage to the heart and blood ves-sels, hemostasis disorders, which aggravate the course of the infection and lead to a significant number of complications both in the acute and subacute phase of the disease, and in the long-term follow-up period. Early detection, diagnosis, as well as prevention and treatment of cardiovascular complications in patients who have undergone COVID-19 will be key to reducing the risk of further adverse health outcomes. The use of low-dose acetylsalicylic acid (ASA) in patients with cardiovascular disease and high cardiovascular risk patients without cardiovascular disease in the post-COVID-19 period is currently considered as one of the main directions of prevention of arterial cardiovascular complications. In this regard, this article discusses the pathogenetic basis of ASA use in patients who have undergone COVID-19, the position of ASA in current clinical guidelines, and the optimal dose and form of ASA for patients who have undergone COVID-19. © 2022, Media Sphera Publishing Group. All rights reserved.
ABSTRACT
The outbreak of the coronavirus disease 2019 (COVID-19) pandemic is an on-going public health emergency that has caused unprecedented morbidity and mortality. COVID-19 is a disease caused by severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), which affects not only the lungs but also the cardiovascular system. A strong theoretical justification for the multisystem effect of COVID-19 is the close relationship between it and endothelial dysfunction, which, according to expert consensus, is crucial for the pathogenesis and severity of the disease. Endothelial dysfunction is considered as the main pathophysiological process in the severe and/or prolonged course of COVID-19, and is probably the common denominator of many clinical aspects of severe COVID-19. This review presents scientific data on the effect of perindopril and amlodipine in patients with hypertension and/or coronary heart disease and COVID-19 on endothelial function. © 2022, Silicea-Poligraf. All rights reserved.